Shahinaz Shalaby

Dr. Shahinaz Shalaby


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
SMSara A. Mohamed
Sara A. Mohamed
SSShahinaz Shalaby
Shahinaz Shalaby
MAMohamed Abdelaziz
Mohamed Abdelaziz
SBSoumia Brakta
Soumia Brakta
WHWilliam D. Hill
William D. Hill
AAAyman Al-Hendy
Ayman Al-Hendy

18 January 2019 in Biomedicines
Verified
Journal Article
Open access
PDF file
SMSara Mohamed
Sara Mohamed
SSShahinaz Shalaby
Shahinaz Shalaby
SBSoumia Brakta
Soumia Brakta
LELelyand Elam
Lelyand Elam
AEAmro Elsharoud
Amro Elsharoud
Ayman A. Al-HendyAyman A. Al-Hendy
Ayman A. Al-Hendy
Background: Premature ovarian insufficiency (POI) is a challenging disease, with limited treatment options at the moment. Umbilical cord blood mesenchymal stem cells (UCMSCs) have demonstrated promising regenerative abilities in several diseases including POI. Materials and Method: A pre-clinical murine case versus vehicle control randomized study. Two experiments ran in parallel in each of the three groups. The first was to prove the ability of UCMSCs in restoring ovarian functions. The second was to prove improved fertility. A total of 36 mice were randomly assigned; 6 mice into each of 3 groups for two experiments. Group 1 (control), group 2 (sham chemotherapy), group 3 (stem cells). Results: In the first experiment, post-UCMSCs treatment (group 3) showed signs of restored ovarian function in the form of increased ovarian weight and estrogen-dependent organs (liver, uterus), increased follicular number, and a significant decrease in FSH serum levels (p < 0.05) compared to group 2, and anti-Mullerian hormone (AMH) serum levels increased (p < 0.05) in group 3 versus group 2. Immuno-histochemistry analysis demonstrated a higher expression of AMH, follicle stimulating hormone receptor (FSHR) and Inhibin A in the growing follicles of group 3 versus group 2. In the second experiment, post-UCMSCs treatment (group 3) pregnancy rates were higher than group 2, however, they were still lower than group 1. Conclusion: We demonstrated the ability of UCMSCs to restore fertility in female cancer survivors with POI and as another source of stem cells with therapeutic potentials.

1 August 2019 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
PDF file
MEmennah elkady
mennah elkady
SSShahinaz Shalaby
Shahinaz Shalaby
FFF Fathi
F Fathi
SES El-Mandouh
S El-Mandouh
Cyclophosphamide (CP) causes premature ovarian failure (POF) due to ovarian toxicity. The toxicity mechanism is attributed to oxidative stress, inflammation, and apoptosis. We assessed whether quercetin and rosuvastatin could promote ovarian protection against CP ovotoxicity. A total of 80 female BALB/c mice were randomly assigned; 10 mice into each of eight groups. Group 1 (control), group 2 (EH), group 3 (CP), group 4 (QH), group 5 (QL), group 6 (RH), group 7 (RL), and group 8 (COM). Quercetin and rosuvastatin groups (4:8) showed signs of restored ovarian function in the form of a significant, dose-dependent increase in primordial follicles number, serum anti-Mullerian hormone level, and ovarian tissue glutathione level (p < 0.05) versus group 3, and a significant, dose-dependent decrease in atretic follicles number and ovarian tissue level of malondialdehyde (p < 0.05) versus group 3. Immunohistochemistry analysis demonstrated a lower expression of caspase and nuclear factor-kappa B of groups (4:8) versus group 3, although quercetin and rosuvastatin showed a nonsignificant reduction in tumor volume. We demonstrated the protective effect of quercetin and rosuvastatin against ovarian toxicity and POF induced by CP without compromising its antitumor effect.

1 June 2016 in Fertility and Sterility
Verified
Journal Article
Closed access
SSShahinaz Shalaby
Shahinaz Shalaby
MKMostafa K. Khater
Mostafa K. Khater
APAymara Mas Perucho
Aymara Mas Perucho
SMSara A. Mohamed
Sara A. Mohamed
IHInas Helwa
Inas Helwa
AAAyman A. Al-Hendy
Ayman A. Al-Hendy

29 July 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
SESally Elnawasany
Sally Elnawasany
YHYusuf Haggag
Yusuf Haggag
SSShahinaz Shalaby
Shahinaz Shalaby
NSNema A. Soliman
Nema A. Soliman
ASAmira A. EL Saadany
Amira A. EL Saadany
Farid BadriaFarid Badria
Farid Badria
Background: liver cancer is one of the most common cancers in the world. So far, there is no gold standard treatment for hepatocellular carcinoma. We conducted this in vitro study to assess the effect of three natural products: Boswellic acids, curcumin and naringin versus corresponding nanoparticles (NPs) on Hep G2 cells proliferation. Methods: Boswellic acid, curcumin, naringin-loaded NPs were prepared using nanoprecipitation method. Human liver (HepG2) cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM). The cell growth inhibition and cytotoxicity were evaluated by MTT assay. Results: Boswellic acid, curcumin, naringin were able to inhibit HepG2 cells proliferation. IC50 at 24 h, 48 h showed significant lower values in NPs versus Free herbs. IC50 values of free Boswellic acids and NPs at 24 h were (24.60 ± 1.89 and 7.78 ± 0.54, P < 0.001), at 48 h were (22.45 ± 1.13 and 5.58 ± 0.27, P < 0.001) respectively. IC50 values of free curcumin and NPs at 24 h were (5.89 ± 0.8 and 3.46 ± 0.23, P < 0.05), at 48 h were (5.57 ± 0.94 and 2.51 ± 0.11, P < 0.05), respectively. For free and naringenin NPs, IC50 values at 24 h were (14.57 ± 1.78 and 7.25 ± 0.17, P < 0.01), at 48 h were (11.37 ± 1.45 and 5.21 ± 0.18, P < 0.01) respectively. Conclusion: Boswellic acid, curcumin, naringin and their nanoprecipitation prepared nanoparticles suppressed Hep G2 cells proliferation.